Correction: J&J Sales
Executive Summary
In the story "Private Grünenthal Aims For Leadership In Pain," (Feb. 21, 2011), "The Pink Sheet" incorrectly reported that the smallest drug on a list of reported drug revenues from Johnson & Johnson for 2010 sold $116 million worldwide. That figure was in fact for fourth quarter 2010 sales. Sales of the oral analgesic Nucynta (tapentadol) seem to be below this apparent reporting threshold, but J&J says it is "pleased" with the drug's performance. "In the two years since the product was approved by FDA, health care professionals have written more than half a million prescriptions for Nucynta, as documented in the IMS National Prescription Audit," the firm states. "In addition, in terms of market share (dollars) for short-acting CII opioids, Nucynta has experienced continued growth for the past four quarters, according to IMS National Sales Perspectives."
You may also be interested in...
Private Grünenthal Aims For Leadership In Pain
Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.